Pharmacy Bulletin

Pharmacy Bulletin

We share important prescription drug information to help you stay informed about updates concerning particular prescription medicines.

VativoRx Bottle update

Korsuva FDA Approved

The U.S. Food and Drug Administration (FDA) approved KorsuvaTM (difelikefalin) injection. The first drug in a new therapy class called kappa opioid receptor (KOR) agonists, it’s also the first drug to be indicated for treating adults who have moderate-to-severe pruritus (chronic itching) associated with chronic kidney disease (CKD) that needs hemodialysis. Aug. 23, 2021

New Growth Hormone, Skytrofa, Approved

Ascendis Pharma received FDA approval for Skytrofa® (lonapegsomatropin- tcgd), a long-acting prodrug of human growth hormone. Aug. 25, 2021

New Opdivo Indication

Bristol Myers Squibb’s Opdivo® (nivolumab) injection became the first programmed death receptor-1 (PD-1) inhibitor to be FDA approved for adjuvant (after surgery) treatment of urothelial carcinoma (bladder cancer). Aug. 19, 2021

Expanded Indication for Xarelto

The peripheral artery disease (PAD) indication for Janssen and Bayer’s Xarelto® (rivaroxaban) tablets was extended by the FDA. Aug. 23, 2021

Tibsovo Gains a New Indication

Under Priority Review, the FDA approved Servier Pharmaceuticals’ Tibsovo® (ivosidenib) tablets as second-line or later treatment for adult patients who have metastatic or advanced isocitrate dehydrogenase-1 (IDH1) mutated cholangiocarcinoma (cancer in the bile ducts). Aug. 25, 2021

Labeling Change for Linzess

Ironwood Pharmaceuticals got FDA approval to revise the boxed warning for Linzess® (linaclotide) capsules. Aug. 24, 2021

New Gvoke Dosage Form Approved

Gvoke® Kit (glucagon) injection was FDA approved. Joining previously available dosage forms Gvoke HypoPen® and Gvoke® PFS, it is used for emergency treatment of patients two years old and older who have diabetes and who are at risk for hypoglycemic episodes. Aug. 20, 2021

Teligent Pharma – Recall of lidocaine topical solution

Teligent Pharma announced a voluntary, patient-level recall of one lot of lidocaine topical solution 4% because testing has found it to be super potent based on an out of specification result obtained at the 18-month stability timepoint. August 27, 2021

This information is shared with you from our partners at OptumRx.

If you’d like to receive the weekly bulletin by email, please let us know.